|
COPYRIGHT 2008 SourceMedia, Inc.
Byline: Richard Kellerhals
Credit Suisse and Wachovia are hoping to inject some life into the leveraged loan market with a new $1 billion term loan B for King Pharmaceuticals, a Bristol, Tenn.-based drug company. Price talk has yet to be determined.
The proceeds from the facility, which will come in two $500 million chunks, will help fund the acquisition ofBridgewater, N.J.-based pharmaceutical company Alpharma. It could not be determined when the banks will syndicate the debt. However, according to the KDP...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
